<DOC>
	<DOCNO>NCT02172118</DOCNO>
	<brief_summary>Study assess influence severe renal impairment pharmacokinetics ( PK ) , safety , select pharmacodynamic ( PD ) parameter BI 1744 CL ( 30 μg administer inhalation Respimat® Inhaler )</brief_summary>
	<brief_title>BI 1744 CL Patients With Severe Renal Impairment Comparison Subjects With Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy subject : Healthy male female subject determine result screen creatinine clearance &gt; 80 mL/min ( Treatment Group 2 ) Age 21 75 year Body Mass Index ( BMI ) &gt; =18.5 &lt; =32 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Renally impaired subject : Renally impaired male female subject ( Treatment Group 1 ) determine result screen follow creatinine clearance estimate accord CockroftGault : Creatinine clearance &lt; 30 mL/min ( Treatment Group 1 , Renal Function Group 4 ) Age 21 75 year BMI &gt; =18.5 &lt; =34 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation Healthy subject meet follow criterion enter trial : Any find medical examination ( include blood pressure ( BP ) [ &gt; 140 mmHg systolic &gt; 95 mmHg diastolic ] , pulse rate ( PR ) electrocardiogram ( ECG ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Relevant gastrointestinal tract surgery ( except appendectomy , herniotomy ) Diseases central nervous system ( epilepsy , seizure ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection ( e.g . include Hepatitis B C HIV ) History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Participation another trial investigational drug within one month previous single dose administration two month previous multiple dose administration prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke confine study site trial day Alcohol abuse ( 40 g/day male , 20 g/day female ) Drug abuse , investigator 's judgement upon review patient 's history urine screening abused substance Veins unsuited iv puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within 48 hour prior trial trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre Subjects able understand comply protocol requirement , instruction protocolstated restriction Renally impaired subject meet follow criterion enter trial : Moderate severe concurrent liver function impairment ( e.g . due hepatorenal syndrome ) Patients significant disease renal impairment exclude . A significant disease define disease opinion investigator put patient risk participation study may influence result study may influence patient 's ability participate study stable condition Diabetic hypertensive patient enter trial disease significant accord criterion . Relevant gastrointestinal tract surgery ( except appendectomy , herniotomy ) Diseases central nervous system ( epilepsy , seizure ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection ( e.g . include Hepatitis B C HIV ) History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial , exclude drug , patient currently take treatment renal concomitant disease Subjects change chronic medication le 4 week prior dose Participation another trial investigational drug within one month previous single dose administration two month previous multiple dose administration prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke confine study site trial day Alcohol abuse ( 40 g/day male , 20 g/day female ) Drug abuse , investigator 's judgement upon review patient 's history urine screening abused substance Veins unsuited iv puncture either arm ( e.g . vein difficult locate , access puncture , vein tendency rupture puncture ) Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within 48 hour prior trial trial ) Clinically relevant laboratory abnormality ( except renal function test deviation clinical laboratory value relate renal impairment ) Hemoglobin &lt; 8 g/dL indicate severe renal anemia ( use erythropoetin allow maintain hematocrit ) Inability comply dietary regimen study centre Subjects able understand comply protocol requirement , instruction protocolstated restriction Systolic blood pressure &lt; 100 &gt; 180 mm Hg , diastolic blood pressure &lt; 60 &gt; 110 mm Hg , pulse rate &lt; 50 &gt; 100 1/min Exclusion criterion specific study due know class side effect profile ß2 mimetics ( healthy renally impaired subject ) : Asthma history pulmonary hyperreactivity Hyperthyrosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia For female subject ( healthy renally impaired ) : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception woman childbearing potential ( adequate contraception : e.g . sterilisation , intrauterine device oral contraception contain ethinyl estradiol ethinyl estradiol additional barrier method ) least 3 month prior participation study Inability maintain adequate contraception whole trial period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>